← Back to dossier
Patient handout

Acute weakness (ED workup — focal + generalized + fluctuating)

PRODUCTION

1. Your condition

This handout is for acute weakness (ed workup — focal + generalized + fluctuating). Your care team identified this based on: focal weakness (hemiparesis / monoparesis / facial droop / dysarthria) — stroke until proven otherwise (powers aha/asa 2019 pmid 31662037; saver nejm 2019).

Other reasons your team may use this plan: generalized symmetric weakness, often ascending — gbs / myopathy / electrolyte / botulism (van den berg brighton gbs pmid 24163275); fatigable / fluctuating weakness + ptosis / diplopia / dysphagia / dysarthria — myasthenic crisis (sanders mgfa 2016 pmid 27358333); episodic / periodic paralysis — channelopathies (hypokalemic, hyperkalemic, thyrotoxic) — k-based phenotype.

4. When to seek emergency care

Call 911 or go to the nearest emergency room right away if you have:

  • Acute focal weakness / facial droop / dysarthria within 4.5 h of last-known-well — IV alteplase / tenecteplase candidate; activate stroke pathway (Powers AHA/ASA 2019 PMID 31662037)(life-threatening)
  • NIHSS ≥6 OR clinical LVO syndrome (gaze deviation, neglect, aphasia, hemiparesis) — CTA head/neck + endovascular thrombectomy ≤24 h (DEFUSE-3 / DAWN) (Powers 2019; Saver NEJM 2019)(life-threatening)
  • Focal deficit fully resolved within 24 h (typically <1 h) — TIA; ABCD2 ≥4 → admit + dual antiplatelet (CHANCE/POINT); urgent vascular workup (Johnston Lancet 2007)
  • Ascending symmetric weakness + areflexia + recent viral illness 1-3 wks prior — Guillain-Barré; LP (albumin-cytologic dissociation) + IVIG 0.4 g/kg/day × 5 d OR PLEX; intubate if FVC<20 (van den Berg 2014 PMID 24163275)(life-threatening)
  • Fatigable weakness + ptosis / diplopia / dysphagia / dysarthria + falling FVC — myasthenic crisis; IVIG or PLEX + pyridostigmine + steroids; intubate if FVC<20 (Sanders MGFA 2016 PMID 27358333)(life-threatening)
  • Bilateral leg weakness + sensory level + saddle anesthesia + urinary retention/incontinence — STAT MRI + dexamethasone 10 mg IV + neurosurgery (Greenberg AAN PMID 12236201; Greenhalgh Spine 2015)(life-threatening)
  • Subacute bilateral weakness + sensory level + bladder dysfunction over hours-days — transverse myelitis; MRI + LP + IV methylprednisolone 1 g × 3-5 d
  • Descending symmetric weakness + cranial nerves (diplopia, dysphagia, dysarthria, dysphonia) + dilated/fixed pupils + autonomic + canned food/wound — botulism; HBAT from CDC + ICU (Sobel CDC PMID 33956777)(life-threatening)
  • Recurrent episodic generalized weakness sparing respirations + K extremes (<2.5 hypoK or >6.5 hyperK) — channelopathy (hypokalemic, hyperkalemic, thyrotoxic); replete K + treat trigger
  • Myalgia + weakness + dark urine + CK >5000 (often >10,000) + heme-positive UA without RBCs → myoglobinuria → AKI risk; aggressive LR + electrolyte correction (Bosch NEJM 2009 PMID 19571284)
  • Na <120 with weakness / AMS / seizure — severe symptomatic hyponatremia; 3% saline 100 mL IV bolus × 1-3 (max 4-6 mEq/L correction in 24 h) → syndrome.hyponatremia.core.v1(life-threatening)
  • Focal deficit with glucose <70 mg/dL — #1 stroke mimic; D50 25 g IV bolus + D10 infusion; reassess neuro exam after glucose ≥100

5. Follow-up

Stroke: secondary prevention (antiplatelet OR anticoag for AFib, statin, BP control, dysphagia screen, rehab); dual-antiplatelet for high-risk TIA (CHANCE/POINT). GBS: outpatient neuro + rehab. MG: chronic immunosuppression + crisis prevention. Cord/cauda: spine surgery + radiation; rehab. Rhabdo: cause workup + electrolyte monitoring. Channelopathy: chronic K replacement + trigger avoidance

6. Sources

Guideline: 2019 AHA/ASA Stroke Guideline (Powers) + 2018-19 DEFUSE-3/DAWN endovascular trials + 2014 van den Berg Brighton GBS + 2016 Sanders MGFA myasthenia + 2009 Bosch NEJM rhabdomyolysis + 2015 CDC Sobel botulism + 2015 Greenberg AAN transverse myelitis + 2015 Stroes EAS statin myopathy + 2007 Johnston Lancet ABCD2 + 2013 CHANCE / 2018 POINT DAPT for TIA

  1. pubmed.ncbi.nlm.nih.gov/33218656
  2. pubmed.ncbi.nlm.nih.gov/9255135